lumpectomy with lymph node dissection for a right-sided breast cancer. Histopathology revealed a 1.5 ϫ 1.1 cm welldifferentiated infiltrating ductal carcinoma with clear margins. Biochemical assays demonstrated the tumor to be ER positive (30%), mildly PR positive (5%), and HER2 gene amplification was negative. The breast parenchyma was treated with postoperative radiotherapy: 5000 cGy to the whole breast with a boost of 1400 cGy to the tumor bed. On the last day of her treatments, no major skin reaction was noted. Based on the biology, the patient was recommended tamoxifen 20 mg per day for 5 years. Within a week of initiating the therapy she developed a painful, diffuse papular rash, which was erythematous and confined to the irradiated area ( Fig. 1 ). The patient did not have any previous history of skin rash or allergies and was not on any other medication at that time. A course of oral cephalexin did not provide any relief. The tamoxifen was discontinued and the patient was prescribed diphenhydramine for symptomatic relief. Gradually over the next few weeks the skin regained normalcy. The patient was restarted on tamoxifen 12 weeks after the initial therapy. Initially, she experienced mild itchiness and minimal erythema, but this did not progress and she continues to take tamoxifen.
Radiation recall dermatitis (RRD) is an inflammatory reaction most often seen in patients with prior exposure to radiation. This rare phenomenon occurs with a variety of cytostatic, 1 and noncytotoxic drugs like simvastatin, interferon alfa-2b, antitubercular medications and tamoxifen. 2 Though the exact mechanism of RDD has not yet been elucidated, authors have suggested radiation induced stem cell depletion, 3 increase in local vascular permeability, 4 overexpression of transforming growth factor ␤ I (TGF-␤ I ) 1 or expression of inflammatory cytokines 3 as possible mechanisms. However, the typical clinical presentation is classic of a drug reaction. This may also explain the increased incidence of RRD on the first exposure 2 indicating the activation of a nonimmune inflammatory pathway. The benefits achieved with steroid therapy 4 further supports this theory.
There have been very few documented cases of tamoxifen-induced RDD and we report one such case. This is surprising because of the widespread use of tamoxifen as an adjuvant for breast cancer therapy since its approval by the FDA in 1990. The diagnosis is one that is easy to overlook because the symptoms may resolve quickly because of the unpredictable course of this condition and this may have contributed to the lack of documented cases. In contrast to the previously reported cases with tamoxifen, our patient developed RRD within 1 week postradiation on starting tamoxifen. It is also imperative to assess the patient for cellulites and malignancy before diagnosing RDD. It has been reported that a rechallenge may produce mild or no recurrence at all. 2 Because the potential benefits usually outweigh the few cutaneous adverse effects of tamoxifen, it could be justifiable to rechallenge the patient with tamoxifen before switching to an alternate therapy. This proved to be the right choice with our patient.
